Erik H Serné Selected Research

Nitroprusside (Sodium Nitroprusside)

11/2011	Obesity is associated with impaired endothelial function in the postprandial state.
9/2008	Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
7/2007	Urinary cortisol is inversely associated with capillary recruitment in women: a potential explanation for the cortisol-blood pressure relationship.
11/2004	Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy.
6/2004	Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance.
5/2002	Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erik H Serné Research Topics

Disease

20	Insulin Resistance 01/2020 - 06/2004
12	Obesity 01/2022 - 11/2004
10	Hyperinsulinism (Hyperinsulinemia) 01/2020 - 05/2002
8	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2011
7	Hypertension (High Blood Pressure) 11/2013 - 11/2004
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2022 - 08/2015
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 08/2011
5	Hyperemia 11/2011 - 05/2002
4	Inflammation (Inflammations) 01/2019 - 12/2006
3	Hypoglycemia (Reactive Hypoglycemia) 01/2018 - 08/2015
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 10/2011 - 06/2004
2	Overweight 10/2019 - 06/2015
2	Venous Thrombosis (Deep-Vein Thrombosis) 11/2018 - 01/2018
2	Necrosis 01/2015 - 03/2006
2	Neoplasms (Cancer) 01/2012 - 04/2010
2	Chronic Renal Insufficiency 01/2012 - 11/2011
1	Hypotension (Low Blood Pressure) 01/2021
1	Pulmonary Embolism 10/2020
1	Body Weight (Weight, Body) 01/2020
1	Cerebral Small Vessel Diseases 01/2019
1	Weight Gain 01/2019
1	Postthrombotic Syndrome 11/2018
1	Venous Thromboembolism 11/2018
1	Dementia (Dementias) 01/2018
1	Venous Insufficiency 01/2018
1	Cognitive Dysfunction 01/2018
1	Alzheimer Disease (Alzheimer's Disease) 01/2018
1	Polyneuropathies (Polyneuropathy) 04/2017
1	Abdominal Obesity 05/2015
1	Hypoxia (Hypoxemia) 05/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2015
1	Atherosclerosis 01/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2012
1	Microvascular Rarefaction 11/2011
1	Vascular Calcification 11/2011

Drug/Important Bio-Agent (IBA)

21	Insulin (Novolin)FDA Link 01/2022 - 05/2002
15	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 01/2009
6	Acetylcholine (Acetylcholine Chloride)FDA Link 11/2011 - 05/2002
6	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 11/2011 - 05/2002
4	Exenatide (Byetta)FDA Link 01/2022 - 06/2015
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2015 - 05/2002
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2018
2	Vasodilator Agents (Vasodilators)IBA 01/2019 - 01/2012
2	GoldIBA 11/2016 - 08/2015
2	AdipokinesIBA 07/2014 - 06/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012 - 04/2010
2	C-Reactive ProteinIBA 08/2011 - 12/2006
2	Nonesterified Fatty Acids (NEFA)IBA 01/2009 - 11/2004
2	SaltsIBA 04/2008 - 09/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2006 - 03/2006
1	dapagliflozinIBA 01/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Troponin T (Troponin T1)IBA 10/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2020
1	Growth Hormone (Somatotropin)IBA 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	p-Aminohippuric Acid (p-Aminohippurate)FDA Link 10/2019
1	omega-N-Methylarginine (NG Monomethyl L Arginine)IBA 10/2019
1	Iloprost (Ventavis)FDA Link 11/2018
1	PolyphenolsIBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2018
1	Blood Glucose (Blood Sugar)IBA 10/2017
1	NAD (NADH)IBA 04/2017
1	Glucagon-Like Peptides (Enteroglucagon)IBA 10/2016
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2016
1	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2016
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 10/2016
1	AdiponectinIBA 03/2016
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2016
1	Hypoglycemic Agents (Hypoglycemics)IBA 08/2015
1	Glucagon-Like Peptide-1 ReceptorIBA 06/2015
1	Transcription Factors (Transcription Factor)IBA 05/2015
1	LipidsIBA 05/2015
1	Tumor Necrosis Factor InhibitorsIBA 01/2015
1	HomocysteineIBA 01/2014
1	ResistinIBA 11/2013
1	Prednisolone (Predate)FDA LinkGeneric 11/2013
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 11/2013
1	GlucocorticoidsIBA 11/2013
1	Bevacizumab (Avastin)FDA Link 01/2012
1	Pharmaceutical PreparationsIBA 01/2012
1	Docetaxel (Taxotere)FDA Link 01/2012
1	Angiogenesis InhibitorsIBA 01/2012
1	MineralsIBA 11/2011
1	Phosphorus (Red Phosphorus)IBA 11/2011
1	Bicarbonates (Hydrogen Carbonate)IBA 11/2011
1	Angiotensin Receptor AntagonistsIBA 10/2011
1	Immunoglobulin M (IgM)IBA 10/2011
1	Valsartan (Vals)FDA Link 10/2011
1	Antirheumatic Agents (DMARD)IBA 08/2011
1	Felodipine (Agon)FDA LinkGeneric 07/2011
1	Calcium Channels (Calcium Channel)IBA 07/2011

Therapy/Procedure

5	Therapeutics 11/2018 - 01/2012
3	Lasers (Laser) 11/2011 - 07/2007
2	Injections 01/2022 - 11/2016
2	Duration of Therapy 11/2018 - 01/2018
1	Compression Stockings 01/2018
1	Glycemic Control 08/2015
1	Drug Therapy (Chemotherapy) 01/2012